GO
Loading...

Enter multiple symbols separated by commas

Biotechnology

More

  • Singapore growth going to hold up: Pro Wednesday, 1 Jan 2014 | 9:51 PM ET
    Singapore Growth Going To Be OK: Pro

    Daryl Liew, Head Of Portfolio Management of REYL Singapore advises investors to look past short-term volatilities in the country's economy after Q4 GDP data missed expectations

  • Biotech index hits an all-time high Thursday, 21 Nov 2013 | 1:32 PM ET
    Biotech index hits an all-time high

    CNBC's Seema Mody reports the biotech index has hit an all-time high in the Nasdaq.

  • JNJ to pay $2.2 billion in US probe: Feds Monday, 4 Nov 2013 | 1:53 PM ET

    Johnson & Johnson and its subsidiaries were accused of promoting powerful psychiatric drugs for unapproved uses in children, seniors and disabled patients.

  • Biotech stocks bounce up Thursday, 10 Oct 2013 | 3:20 PM ET
    Biotech stocks bounce up

    CNBC's Seema Mody reports on the biggest movers in the Nasdaq including social media stocks like Facebook up 5 percent.

  • NPS Pharma CEO talks life changing treatment

    Francois Nader, NPS Pharmaceuticals president & CEO, discusses its lead product Gattex for "short bowel syndrome," the potential for Netpara and the solid performance of its stock.

  • How to play the biotech boom Monday, 7 Oct 2013 | 2:36 PM ET
    How to play the biotech boom

    Biotech stocks are some of Nasdaq's best performing this year. Joel Sendek, Stifel Nicolaus, looks at names leading the biotech boom.

  • Shutdown not huge for biotech: Pro Tuesday, 1 Oct 2013 | 5:40 PM ET
    Shutdown not huge for biotech: Pro

    How are biotech companies and the FDA impacted by the government shutdown? Yaron Werber of Citi Investment Research, offers insight.

  • Array Biopharma CEO: Developing products ourselves Friday, 27 Sep 2013 | 6:50 PM ET
    Array Biopharma CEO: Developing products ourselves

    Mad Money host Jim Cramer calls Array BioPharma a spec play. The company has 6 trials in phase 3 in progress. Its CEO Ron Squarer discusses its partnerships with big players including Novartis and Celgene.

  • Man fitted with first mind-controlled bionic leg Thursday, 26 Sep 2013 | 11:07 AM ET

    Zac Vawter has been fitted with the first thought-controlled bionic leg, scientists at the Rehabilitation Institute of Chicago reported.

  • Cramer: Forget government shutdown, invest here Thursday, 26 Sep 2013 | 10:14 AM ET

    Want to avoid taking a hit on your portfolio because of troubles in Washington? Cramer found one sector that will be a shelter from the storm.

  • Amgen to buy Onyx for more than $10 billion Monday, 26 Aug 2013 | 7:51 AM ET
    amgen-200.jpg

    Amgen has struck a $10 billion-plus deal to buy Onyx Pharmaceuticals, ending a two-month-long auction for the cancer drugmaker.

  • Amgen close to buying Onyx for $125 per share Saturday, 24 Aug 2013 | 5:32 PM ET
    amgen-200.jpg

    Amgen is close to buying Onyx for $125 per share, or more than $10 billion, in a deal that is expected to be announced as soon as Monday, two people familiar with the matter said on Saturday.

  • Apple shares hit 6-month highs Tuesday, 13 Aug 2013 | 1:30 PM ET
    Apple shares hit 6-month highs

    CNBC's Seema Mody reports the biggest movers in the Nasdaq including Apple, and biotech stocks.

  • Cloned horses may soon compete at US racetracks Tuesday, 13 Aug 2013 | 12:53 PM ET
    The head of cloning company Cryozootech, Eric Palmer, posing with a cloned horse Pieraz-Cryozootech-Stallion during its presentation to the press. The horse is a pure-bred Arab, from a castrated endurance champion, Pieraz.

    A judge ordered the American Quarter Horse Association to allow cloned horses to be entered into the breed's official registry, which could clear the way for the clones to race.

  • Seed giants try to change image of GMO crops Tuesday, 30 Jul 2013 | 11:21 AM ET
    A research biologist takes tissue samples from genetically modified corn plants inside a climate chamber housed in Monsanto agribusiness headquarters in St Louis.

    In an effort to clean up the image of genetically modified crops, major seed and crop science companies launched GMOAnswers.com to answer questions about so-called GMOs.

  • Biotech's boom, can it continue? Wednesday, 24 Jul 2013 | 2:35 PM ET
    Biotech's boom, can it continue?

    Biotech stocks are some of the best-performing S&P stocks this month. Chris Raymond, senior biotech analyst at Robert W. Baird, shares his top picks.

  • Health Care, Wealth, and Happiness Wednesday, 10 Jul 2013 | 12:18 PM ET
    Health Care, Wealth, and Happiness

    Health care stocks have been up almost across the board since 2010. Biotech and insurance names have been up triple digits. But political developments have put health care on a rockier path. CNBC's Kate Kelly breaks down the sector.

  • Genetic Modification: Seed Companies Fight Back Tuesday, 25 Jun 2013 | 4:10 PM ET

    Genetically modified seeds are used in corn and soybeans grown in the US, but the debate over the effects of tinkering with Mother Nature hasn't gone away.

  • Rising Rates Are Not a Bad Rx for Pharma: Ryan Thursday, 20 Jun 2013 | 3:27 PM ET

    Independent of the debate on the Federal Reserve and interest rates, FTI Consulting's Barbara Ryan expects pharmaceutical and biotech stocks can continue to do well.

  • Labels on bags of snack foods indicate they are non-GMO food products.

    Last year $2 billion worth of products were sold with a label saying they do not contain ingredients from genetically modified organisms, but the claim wasn't backed by regulators.